We report the case of a 44-year-old male patient with an aggressive silent corticotroph cell
pituitary adenoma, subtype 2. In that it progressed to carcinoma despite temozolomide …

Especially given the rarity of aggressive pituitary tumors and carcinomas, and the scarcity of
available data, the ESE guidelines are of tremendous help, providing clinicians with vital …

Pituitary tumors are common in the general population. Since neuroimaging techniques
have improved, pituitary tumors are more often diagnosed incidentally. About 16.7% of the …

Pituitary tumors are mostly benign lesions, although 5–35% are locally invasive. A small
number exhibit a more aggressive course, infiltrating dura, bone and sinuses, and are …

Background Invasive pituitary adenomas often recurred after postoperative radiotherapy and
are difficult to treat. Temozolomide is an alkylating cytostaticum and has been reported to …

BACKGROUND: Patients with metastatic poorly differentiated endocrine carcinoma (PDEC)
usually have a short survival. The chemotherapy combination of cisplatin and etoposide is …

Clinically nonfunctioning adenomas range from being completely asymptomatic, and
therefore detected either at autopsy or as incidental findings on head MRI or CT scans …

We report a 64-year-old male who presented to our department in 2007 with bitemporal
hemianopia secondary to a large recurrent pituitary prolactinoma in the sellar region and …

4044 Background: Inhibitors of the VEGF pathway have been shown to have activity in
neuroendocrine tumors (NETs). Temozolomide (TMZ), an oral analog of dacarbazine is also …

Temozolomide, a new oral cytotoxic agent, has been given to 28 patients with primary brain
tumours. Treatment was given at a dose of 150 mg/m 2/day for 5 days (ie total dose 750 …